MIT Institute Professor Robert Langer Joins Accelrys NanoBiology Initiative Scientific Advisory Committee
|Drs. Robert Langer and Leroy Hood to Guide Development of Nanotechnology-Based Pharmaceutical and Diagnostics Design IT Solutions|
“The intersection of materials science and biotechnology is in my mind one of the most interesting, dynamic emerging fields today. Broadening our ability to predict and engineer nanotechnology and nanoscale materials at that interface is a critical next step”
Accelrys, Inc. (NASDAQ:ACCL), a leading provider of scientific modeling and workflow software solutions, announced that Dr. Robert Langer, institute professor in chemical and biomedical engineering at the Massachusetts Institute of Technology, has joined the Scientific Advisory Committee (SAC) of the Accelrys NanoBiology Initiative. Providing an international collaborative framework for its members in academia, government and industry, the Accelrys NanoBiology Initiative will assess and develop the IT solutions that address critical challenges of nanotechnology-enabled pharmaceutical and diagnostic design. Offering his technical and scientific guidance, Dr. Langer has joined Initiative Chair Dr. Leroy Hood, president of the Institute for Systems Biology, as the second member of the NanoBiology Initiative SAC.
As nanotechnology is increasingly applied to biomedical research and product development, powerful modeling, simulation and analytical tools can enable engineers and scientists to efficiently assess and develop those highly complex systems. The Accelrys NanoBiology Initiative offers members the opportunity to define and prioritize the most critical challenges in this nascent sector and directly influence the fundamental software solutions. The Initiative will leverage Accelrys' core strengths in life science modeling, materials modeling, informatics, and workflow technology to develop a comprehensive infrastructure that can enable predictive design and analysis of novel drug delivery platforms, as well as the optimization of devices for biosensing, imaging, and diagnostics.
"The intersection of materials science and biotechnology is in my mind one of the most interesting, dynamic emerging fields today. Broadening our ability to predict and engineer nanotechnology and nanoscale materials at that interface is a critical next step," said Dr. Robert Langer. "As part of the NanoBiology Initiative's efforts, we'll be addressing the challenge of effectively integrating computational modeling into the entire interdisciplinary research and design process for biomedical science and engineering, shifting the nanobiology R&D paradigm to one of more informed experimentation."
One of only 13 Institute Professors, MIT's highest faculty member honor, Dr. Robert Langer has written more than 880 articles and filed nearly 550 patents worldwide, more than 180 of which have been licensed to pharmaceutical, chemical, biotechnology and medical device companies. Forbes Magazine and Bio World have named Dr. Langer one of the 25 most important individuals in biotechnology. Dr. Langer has also served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 to 2002 and as chairman from 1999 to 2002.
"With Dr. Langer, a preeminent scientist in the field of drug delivery, joining molecular biology pioneer Dr. Leroy Hood on our Scientific Advisory Committee, our Initiative members have access to superb scientific guidance," said Mark Emkjer, president and chief executive officer of Accelrys. "In their advisory roles, these two great minds, both leaders at the intersection of nanotech and the life sciences, will help us address the significant need for next-generation technology solutions that further research efforts and in turn help our pharmaceutical and biomedical customers bring innovative products to market as efficiently as possible."
To learn more about the Initiative or register for the upcoming informational US seminar series scheduled August 8-15th in four cities nationwide visit: http://www.accelrys.com/info/initiatives/nanobio/index.html
Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, modeling, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design, as well as drug discovery and development. SciTegic, Inc., a wholly owned subsidiary of Accelrys, has pioneered a new technology platform called "data pipelining" to process research discovery data with unprecedented flexibility. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. For more information about Accelrys, visit its website at http://www.accelrys.com/.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements, including statements relating to the NanoBiology Initiative and products resulting therefrom, are subject to risks and uncertainties including, but not limited to, the risks that the initiative will not be successful and that it will not result in the timely or successful development or commercialization of software, as well as risks relating to market acceptance or demand relating to the initiative or software, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act and, disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.